Dr. Ajit Chande

Assistant Professor
Biological Sciences
Indian Institute of Science Education and Research, Bhopal
India

Professor Pathology
Biography

Assistant Professor (May 2017-till date), Biological Sciences, Indian Institute of Science Education and Research, Bhopal, India. Postdoctoral Fellow (July 2014-April 2017), Centre for Integrative Biology, University of Trento, Italy Research Scientist (Jan 2012-June 2014), Immunology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi. Ph.D. (August 2006-December 2011), Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Navi Mumbai.

Research Intrest

In the molecular arms race between viruses and their host cells, each side employs multiple strategies to deal with the other. Whereas the host has sophisticated antiviral signaling programs to combat viral infection, viruses evolved their own proteins to subvert these host defenses. Studies towards resolving these interactions and pathogen’s evasion tactics, however, may potentially translate into alternate therapeutic strategies to reduce the disease burden. We have recently identified a cellular factor SERINC5 that potently inhibits HIV-1, MLV and EIAV. This host-factor has a broad spectrum activity and we have identified that three different retroviruses have developed countermeasures to inhibit this host restriction. We are currently trying to understand such cell-intrinsic mechanisms of viral inhibition and investigating the existence of further cross-species anti-retroviral barriers. Based on the strengths in cellular engineering and assay development, our research group is also interested in developing innovative molecular technology enabling novel approaches to study, diagnose and treat diseases. We exploit the CRISPR/Cas9 genome editing technologies for our own research interests in viral pathogenesis, and in collaboration with experts within and outside of India. For development and exploitation of our technologies in other fields, we collaborate intensively. At the moment, our strategic technology development focuses on cellular engineering as a basis for the discovery and development of novel biopharmaceuticals.

List of Publications
Modeling and experimental analyses reveals signaling plasticity in a bi-modular assembly of CD40 receptor activated kinases U Sarma, A Sareen, M Maiti, V Kamat, R Sudan, S Pahari, N Srivastava, ... PloS one 7 (7), e39898
Leishmania donovani targets tumor necrosis factor receptor-associated factor (TRAF) 3 for impairing TLR4-mediated host response P Gupta, J Giri, S Srivastav, AG Chande, R Mukhopadhyaya, PK Das, ... The FASEB Journal 28 (4), 1756-1768
Leishmania donovani exploits host deubiquitinating enzyme A20, a negative regulator of TLR signaling, to subvert host immune response S Srivastav, S Kar, AG Chande, R Mukhopadhyaya, PK Das The Journal of Immunology 189 (2), 924-934
Uncoupling protein 2 negatively regulates mitochondrial reactive oxygen species generation and induces phosphatase-mediated anti-inflammatory response in experimental visceral leishmaniasis WB Ball, S Kar, M Mukherjee, AG Chande, R Mukhopadhyaya, PK Das The Journal of Immunology 187 (3), 1322-1332
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation A Rosa, A Chande, S Ziglio, V De Sanctis, R Bertorelli, SL Goh, ... Nature 526 (7572), 212
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer A Dutt, AH Ramos, PS Hammerman, C Mermel, J Cho, T Sharifnia, ... PloS one 6 (6), e20351